A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer

Prior treatment

• Pregnant or lactating patients or male or female patients of reproductive potential who are not willing to employ highly effective birth control from screening to 6 months after the last dose of chemotherapy

Other illness

• Participation in an interventional trial for pancreatic cancer during the study data collection period
• Patients with the presence of implanted cardiac pacemakers, defibrillators, electronic devices or implanted devices with metal parts in the thoracic cavity at the time of IRE

Other

• Patients who are unable to tolerate general anesthetic with full skeletal muscle blockade

• Provisions of signed and dated informed consent form
• Patient is 18 years of age and older
• Patient has a diagnosis of Stage 3 PC cytologically or pathologically confirmed per American Joint Committee on Cancer (AJCC) staging criteria
• Patient has a tumor evaluated as Stage 3 according to National Comprehensive Cancer Network (NCCN) guidelines, based on radiographic imaging or exploratory surgery
• Maximum axial and anterior to posterior tumor dimension of ≤3.5cm after SOC
• Patient has received 3 months of SOC per each participating institution's guidelines
• Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Patient has an American Society of Anesthesiologists (ASA) classification of physical health status of 1 or 2.
• Patients at IRE sites who are deemed eligible for IRE and receive ablation using the NanoKnife System
• Patient shows no evidence of disease progression based on NCCN guidelines after completing three (3) months of SOC